Certolizumab pegol: Difference between revisions

Jump to navigation Jump to search
m (Protected "Certolizumab pegol": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
Line 1: Line 1:
{{EH}}
 
{{SI}}
{{SI}}


Line 18: Line 18:


{{humanizedmonoclonals}}
{{humanizedmonoclonals}}
{{SIB}}
 


[[Category:Monoclonal antibodies]]
[[Category:Monoclonal antibodies]]

Revision as of 23:41, 8 August 2012

WikiDoc Resources for Certolizumab pegol

Articles

Most recent articles on Certolizumab pegol

Most cited articles on Certolizumab pegol

Review articles on Certolizumab pegol

Articles on Certolizumab pegol in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Certolizumab pegol

Images of Certolizumab pegol

Photos of Certolizumab pegol

Podcasts & MP3s on Certolizumab pegol

Videos on Certolizumab pegol

Evidence Based Medicine

Cochrane Collaboration on Certolizumab pegol

Bandolier on Certolizumab pegol

TRIP on Certolizumab pegol

Clinical Trials

Ongoing Trials on Certolizumab pegol at Clinical Trials.gov

Trial results on Certolizumab pegol

Clinical Trials on Certolizumab pegol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Certolizumab pegol

NICE Guidance on Certolizumab pegol

NHS PRODIGY Guidance

FDA on Certolizumab pegol

CDC on Certolizumab pegol

Books

Books on Certolizumab pegol

News

Certolizumab pegol in the news

Be alerted to news on Certolizumab pegol

News trends on Certolizumab pegol

Commentary

Blogs on Certolizumab pegol

Definitions

Definitions of Certolizumab pegol

Patient Resources / Community

Patient resources on Certolizumab pegol

Discussion groups on Certolizumab pegol

Patient Handouts on Certolizumab pegol

Directions to Hospitals Treating Certolizumab pegol

Risk calculators and risk factors for Certolizumab pegol

Healthcare Provider Resources

Symptoms of Certolizumab pegol

Causes & Risk Factors for Certolizumab pegol

Diagnostic studies for Certolizumab pegol

Treatment of Certolizumab pegol

Continuing Medical Education (CME)

CME Programs on Certolizumab pegol

International

Certolizumab pegol en Espanol

Certolizumab pegol en Francais

Business

Certolizumab pegol in the Marketplace

Patents on Certolizumab pegol

Experimental / Informatics

List of terms related to Certolizumab pegol

Overview

Certolizumab pegol (CDP870) is a PEGylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody.

It is the subject of phase III clinical trials in both Crohn's disease[1] and rheumatoid arthritis. [2]

Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol vs placebo in moderate to severe active Crohn's disease.

In addition, data from both trials suggest it is well-tolerated. As yet its efficacy has not been directly compared to other anti-TNF-alpha agents.

References

  1. Sandborn WJ, Feagan BG, Stoinov S; et al. (2007). "Certolizumab pegol for the treatment of Crohn's disease". N. Engl. J. Med. 357 (3): 228–38. doi:10.1056/NEJMoa067594. PMID 17634458.
  2. Kaushik VV, Moots RJ (2005). "CDP-870 (certolizumab) in rheumatoid arthritis". Expert opinion on biological therapy. 5 (4): 601–6. doi:10.1517/14712598.5.4.601. PMID 15934837.

External links

Template:Humanizedmonoclonals

Template:WS